JAGUAR HEALTH, INC. Amortization of Intangible Assets
JAGUAR HEALTH, INC. (JAGX) reported Amortization of Intangible Assets of $467.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-19
- JAGUAR HEALTH, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $467.00K, a 0.00% change year-over-year.
- JAGUAR HEALTH, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $467.00K, a 0.00% change year-over-year.
- JAGUAR HEALTH, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $500.00K, a 0.00% change year-over-year.
- JAGUAR HEALTH, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $468.00K, a 1.52% increase year-over-year.
- JAGUAR HEALTH, INC. amortization of intangible assets for fiscal 2025 was $1.90M, a 0.00% change from fiscal 2024.
- JAGUAR HEALTH, INC. amortization of intangible assets for fiscal 2024 was $1.90M, a 5.00% decline from fiscal 2023.
- JAGUAR HEALTH, INC. amortization of intangible assets for fiscal 2023 was $2.00M, a 11.11% increase from fiscal 2022.
- JAGUAR HEALTH, INC. amortization of intangible assets for fiscal 2022 was $1.80M, a 5.88% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed | Amortization of Intangible Assets 18 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $467.00K 10-Q · filed 2026-08-19 | $934.00K 10-Q · filed 2026-08-19 | $1.43M derived: sum of 3 quarters · filed 2026-08-19 | $1.90M derived: sum of 4 quarters · filed 2026-08-19 | |||||
| 2026-03-31 | $467.00K 10-Q · filed 2026-05-20 | $967.00K derived: sum of 2 quarters · filed 2026-05-20 | $1.44M derived: sum of 3 quarters · filed 2026-05-20 | $1.90M derived: sum of 4 quarters · filed 2026-08-19 | |||||
| 2025-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | $968.00K derived: sum of 2 quarters · filed 2026-04-07 | $1.44M derived: sum of 3 quarters · filed 2026-08-19 | $1.90M 10-K · filed 2026-04-07 | |||||
| 2025-09-30 | $468.00K 10-Q · filed 2025-11-14 | $935.00K derived: sum of 2 quarters · filed 2026-08-19 | $1.40M 10-Q · filed 2025-11-14 | $1.90M derived: sum of 4 quarters · filed 2026-08-19 | |||||
| 2025-06-30 | $467.00K 10-Q · filed 2026-08-19 | $934.00K 10-Q · filed 2026-08-19 | $1.43M derived: sum of 3 quarters · filed 2026-08-19 | $1.90M derived: sum of 4 quarters · filed 2026-08-19 | |||||
| 2025-03-31 | $467.00K 10-Q · filed 2026-05-20 | $967.00K derived: sum of 2 quarters · filed 2026-05-20 | $1.43M derived: sum of 3 quarters · filed 2026-05-20 | $1.86M derived: sum of 4 quarters · filed 2026-05-20 | |||||
| 2024-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | $961.00K derived: sum of 2 quarters · filed 2026-04-07 | $1.40M derived: sum of 3 quarters · filed 2026-04-07 | $1.90M 10-K · filed 2026-04-07 | |||||
| 2024-09-30 | $461.00K 10-Q · filed 2025-11-14 | $895.00K derived: sum of 2 quarters · filed 2025-11-14 | $1.40M 10-Q · filed 2025-11-14 | $1.88M derived: sum of 4 quarters · filed 2025-11-14 | |||||
| 2024-06-30 | $434.00K 10-Q · filed 2025-08-14 | $923.00K 10-Q · filed 2025-08-14 | $1.42M derived: sum of 3 quarters · filed 2025-08-14 | $1.91M derived: sum of 4 quarters · filed 2025-08-14 | |||||
| 2024-03-31 | $489.00K 10-Q · filed 2025-05-15 | $989.00K derived: sum of 2 quarters · filed 2025-05-15 | $1.48M derived: sum of 3 quarters · filed 2025-05-15 | $1.97M derived: sum of 4 quarters · filed 2025-05-15 | |||||
| 2023-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $989.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.48M derived: sum of 3 quarters · filed 2025-03-31 | $2.00M 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | $489.00K 10-Q · filed 2024-11-13 | $977.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.50M 10-Q · filed 2024-11-13 | $1.97M derived: sum of 4 quarters · filed 2024-11-13 | |||||
| 2023-06-30 | $488.00K 10-Q · filed 2024-08-13 | $976.00K 10-Q · filed 2024-08-13 | $1.48M derived: sum of 3 quarters · filed 2024-08-13 | $1.96M derived: sum of 4 quarters · filed 2024-08-13 | |||||
| 2023-03-31 | $488.00K 10-Q · filed 2024-05-14 | $988.00K derived: sum of 2 quarters · filed 2024-05-14 | $1.47M derived: sum of 3 quarters · filed 2024-05-14 | $1.89M derived: sum of 4 quarters · filed 2024-05-14 | |||||
| 2022-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $983.00K derived: sum of 2 quarters · filed 2024-04-01 | $1.41M derived: sum of 3 quarters · filed 2024-04-01 | $1.80M 10-K · filed 2024-04-01 | |||||
| 2022-09-30 | $483.00K 10-Q · filed 2023-11-14 | $905.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.30M 10-Q · filed 2023-11-14 | $1.72M derived: sum of 4 quarters · filed 2023-11-14 | |||||
| 2022-06-30 | $422.00K 10-Q · filed 2023-08-14 | $843.00K 10-Q · filed 2023-08-14 | $1.24M derived: sum of 3 quarters · filed 2023-08-14 | $1.66M derived: sum of 4 quarters · filed 2023-08-14 | |||||
| 2022-03-31 | $418.00K 10-Q · filed 2023-05-15 | $818.00K derived: sum of 2 quarters · filed 2023-05-15 | $1.24M derived: sum of 3 quarters · filed 2023-05-15 | $1.66M derived: sum of 4 quarters · filed 2023-05-15 | |||||
| 2021-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $822.00K derived: sum of 2 quarters · filed 2023-03-24 | $1.24M derived: sum of 3 quarters · filed 2023-03-24 | $1.70M 10-K · filed 2023-03-24 | |||||
| 2021-09-30 | $422.00K 10-Q · filed 2022-11-14 | $844.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.30M 10-Q · filed 2022-11-14 | $1.67M derived: sum of 4 quarters · filed 2022-11-14 | |||||
| 2021-06-30 | $422.00K 10-Q · filed 2022-08-22 | $844.00K 10-Q · filed 2022-08-22 | $1.24M derived: sum of 3 quarters · filed 2022-08-22 | $1.67M derived: sum of 4 quarters · filed 2022-08-22 | $843.00K 10-Q · filed 2021-08-13 | ||||
| 2021-03-31 | $422.00K 10-Q · filed 2021-05-17 | $822.00K derived: sum of 2 quarters · filed 2022-03-11 | $1.24M derived: sum of 3 quarters · filed 2022-03-11 | $1.67M derived: sum of 4 quarters · filed 2022-03-11 | |||||
| 2020-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $822.00K derived: sum of 2 quarters · filed 2022-03-11 | $1.24M derived: sum of 3 quarters · filed 2022-03-11 | $1.70M 10-K · filed 2022-03-11 | |||||
| 2020-09-30 | $422.00K 10-Q · filed 2021-11-17 | $844.00K derived: sum of 2 quarters · filed 2021-11-17 | $1.30M 10-Q · filed 2021-11-17 | $422.00K 10-Q · filed 2020-11-16 | $1.70M derived: sum of 4 quarters · filed 2021-11-17 | ||||
| 2020-06-30 | $422.00K 10-Q · filed 2021-08-13 | $422.00K 10-Q · filed 2020-08-13 | $1.28M derived: sum of 3 quarters · filed 2021-08-13 | $2.54M derived: sum of 4 quarters · filed 2021-08-13 | |||||
| 2020-03-31 | $422.00K 10-Q · filed 2021-05-17 | $857.00K derived: sum of 2 quarters · filed 2021-05-17 | $2.12M derived: sum of 3 quarters · filed 2021-05-17 | $2.96M derived: sum of 4 quarters · filed 2021-05-17 | |||||
| 2019-12-31 | $435.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $1.70M derived: sum of 2 quarters · filed 2021-03-31 | $2.54M derived: sum of 3 quarters · filed 2021-03-31 | $1.70M 10-K · filed 2021-03-31 | $1.69M 10-K · filed 2020-04-03 | ||||
| 2019-09-30 | $1.26M 10-Q · filed 2020-11-16 | $421.67K 10-Q · filed 2019-11-14 | $2.11M derived: sum of 2 quarters · filed 2020-11-16 | $1.26M 10-Q · filed 2020-11-16 | $1.27M 10-Q · filed 2019-11-14 | $2.95M derived: sum of 4 quarters · filed 2020-11-16 | |||
| 2019-06-30 | $843.00K 10-Q · filed 2020-08-13 | $421.67K 10-Q · filed 2019-08-14 | $843.00K 10-Q · filed 2020-08-13 | $421.67K 10-Q · filed 2019-08-14 | $1.69M derived: sum of 3 quarters · filed 2020-08-13 | $2.11M derived: sum of 4 quarters · filed 2020-08-13 | |||
| 2019-03-31 | $422.00K 10-Q · filed 2020-05-15 | $421.67K 10-Q · filed 2019-05-21 | $843.66K derived: sum of 2 quarters · filed 2020-05-15 | $1.27M derived: sum of 3 quarters · filed 2020-05-15 | $2.11M derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | $421.66K derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-03 | $843.32K derived: sum of 2 quarters · filed 2020-04-03 | $1.69M derived: sum of 3 quarters · filed 2020-04-03 | $1.69M 10-K · filed 2020-04-03 | |||||
| 2018-09-30 | $421.67K 10-Q · filed 2019-11-14 | $1.27M derived: sum of 2 quarters · filed 2019-11-14 | $1.27M 10-Q · filed 2019-11-14 | $1.26M 10-Q · filed 2018-11-19 | $2.11M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | $843.33K 10-Q · filed 2019-08-14 | $421.67K 10-Q · filed 2018-08-13 | $843.33K 10-Q · filed 2019-08-14 | $843.33K 10-Q · filed 2018-08-13 | $1.69M derived: sum of 3 quarters · filed 2019-08-14 | $1.97M derived: sum of 4 quarters · filed 2019-08-14 | |||
| 2018-03-31 | $421.67K 10-Q · filed 2019-05-21 | $843.33K derived: sum of 2 quarters · filed 2019-05-21 | $1.12M derived: sum of 3 quarters · filed 2019-05-21 | $1.12M derived: sum of 4 quarters · filed 2019-05-21 | |||||
| 2017-12-31 | $421.67K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | $702.78K derived: sum of 2 quarters · filed 2019-04-10 | $702.78K derived: sum of 3 quarters · filed 2019-04-10 | $702.78K 10-K · filed 2019-04-10 | |||||
| 2017-09-30 | $281.11K 10-Q · filed 2018-11-19 | $281.11K derived: sum of 2 quarters · filed 2018-11-19 | $281.11K 10-Q · filed 2018-11-19 | ||||||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-13 | $0.00 10-Q · filed 2018-08-13 | |||||||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |